LIXTE Biotechnology Holdings has appointed Sidney Braun as Chief Executive Officer of its Liora Technologies Europe Ltd. subsidiary. Braun, who previously facilitated LIXTE's November 2025 acquisition of Liora's assets, brings more than 20 years of healthcare operational and strategic advisory experience to the role. Management stated the appointment supports its strategy to scale the technology and pursue a recurring revenue model within the radiotherapy segment of cancer care.
The appointment is significant as Braun will lead advancement of Liora's LiGHT System, an electronically controlled proton therapy platform designed to enhance tumor treatment. Proton therapy represents an advanced form of radiation treatment that can target tumors more precisely than conventional radiation, potentially reducing damage to surrounding healthy tissue. The technology's development aligns with growing demand for more targeted cancer therapies that improve patient outcomes while minimizing side effects.
LIXTE Biotechnology Holdings is a clinical-stage pharmaceutical and med-tech company advancing cancer treatments. The company has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data available at https://www.lixte.com, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.
LIXTE's lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology called activation lethality that is advancing a new treatment paradigm. The company's new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer.
The European expansion through the Liora Technologies subsidiary represents a strategic move to access international markets for advanced radiotherapy systems. The appointment of an experienced healthcare executive like Braun suggests LIXTE is moving from research and development toward commercialization of its technologies. This development matters because it signals progress in bringing advanced proton therapy systems to market, potentially expanding treatment options for cancer patients globally.
The full press release can be viewed at https://ibn.fm/9kbfE. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer.
